They just started their GOG trial in the US that will supplement the Indian trial which is 80% complete(phase 2). They already have 1 total response and 3 other partial responses in the first 31 patients dosed with more to come. They will be giving Efficacy results on January 25th at the world vaccine congress. They are also running a parallel phase 2 in CIN which looks to be 1/2 way done and will be reporting on their low dose cohort toward the end of february. They also have a head and neck cancer trial starting soon in the UK (phase 2) that the CRUK will fund 100% through phase 3. Their cost of production is 6.00 a dose and have had 0 serious side effects in over 300 administrations. Oh and I forgot to mention, We've got like 3 previous(?) Bristol Meyers Squibb employees working at our little unknown company! WERE CURRENTLY TRADING AT .165 CENTS A SHARE!